Xencor, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
XNCR Nasdaq 2830 www.xencor.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Xencor, Inc.

[Latest] Global T-Cell Engagers Market Size/Share Worth USD 18.8 Billion by 2034 at a 21.2% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) - Jan 14th, 2026 1:30 am
Xencor Highlights Corporate Priorities and 2026 Pipeline Milestones - Jan 8th, 2026 6:01 am
Calculating The Fair Value Of Xencor, Inc. (NASDAQ:XNCR) - Dec 31st, 2025 3:46 am
Xencor Announces Extension of U.S. Patent Term on Certain Xtend™ Antibodies - Dec 9th, 2025 5:00 am
Xencor (XNCR): Assessing Valuation After Net Losses Narrow Sharply in Latest Earnings - Nov 14th, 2025 4:14 am
Will Sharply Reduced Net Losses Signal a Turning Point for Xencor's (XNCR) Path to Profitability? - Nov 13th, 2025 2:10 pm
Xencor to Participate at Upcoming Investor Conferences - Nov 10th, 2025 2:01 pm
Xencor (XNCR) Reports Q3 Loss, Misses Revenue Estimates - Nov 5th, 2025 3:35 pm
Xencor: Q3 Earnings Snapshot - Nov 5th, 2025 2:47 pm
Xencor Reports Third Quarter 2025 Financial Results - Nov 5th, 2025 2:01 pm
Beaten Down by 35%-Plus: Analysts Say These 2 Oversold Stocks Are Poised to Turn the Corner - Nov 5th, 2025 4:08 am
Aurinia Pharmaceuticals (AUPH) Surpasses Q3 Earnings and Revenue Estimates - Nov 4th, 2025 5:10 am
Xencor (XNCR): Evaluating Valuation Following Early XmAb819 Trial Results Announcement - Oct 28th, 2025 10:53 pm
Could Xencor's (XNCR) Early Cancer Data Reveal a New Edge in Its Innovation Strategy? - Oct 27th, 2025 8:04 pm
Xencor Presents Initial Data for XmAb819, a First-in-class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Clear Cell Renal Cell Carcinoma - Oct 24th, 2025 10:30 am
Xencor to Host Webcast and Conference Call to Discuss Initial Results from the Ongoing Phase 1 Dose-Escalation Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma - Oct 21st, 2025 6:01 am
Xencor Stock Earns Relative Strength Rating Upgrade - Oct 16th, 2025 11:40 am
Xencor Announces Presentation of Initial Phase 1 Dose-Escalation Results of XmAb819 in Clear Cell Renal Cell Carcinoma at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - Oct 14th, 2025 10:45 am
Tracking the Evolving Narrative for Xencor After Mixed Analyst Developments - Oct 8th, 2025 9:08 pm
Strength Seen in Xencor (XNCR): Can Its 7.3% Jump Turn into More Strength? - Sep 18th, 2025 8:05 am